-
公开(公告)号：US20170360823A1
公开(公告)日：2017-12-21
申请号：US15696111
申请日：2017-09-05
申请人： Baxalta Incorporated , Baxalta GmbH
发明人： Michael Dockal , Fritz Scheiflinger , Sabine Knappe , Susanne Till , Ton Hai , Paul Sanders , Prasad Dande , Cong Jiang
IPC分类号： A61K31/737 , C07H5/10 , A61K45/06 , C08B37/16 , A61K31/715
CPC分类号： A61K31/737 , A61K31/715 , A61K45/06 , C07H5/10 , C08B37/0012 , A61K2300/00
摘要： The present invention provides non-anticoagulant sulfated or sulfonated polysaccharides (NASPs), which accelerate the blood clotting process. Also provided are pharmaceutical formulations comprising a NASP of the invention in conjunction with a pharmaceutically acceptable excipient and, in various embodiments, these formulations are unit dosage formulations. The invention provides a NASP formulation, which is orally bioavailable. Also provided are methods for utilizing the compounds and formulations of the invention to promote blood clotting in vivo as therapeutic and prophylactic agents and in vitro as an aid to studies of the blood clotting process.
-
公开(公告)号：US20170281671A1
公开(公告)日：2017-10-05
申请号：US15627332
申请日：2017-06-19
申请人： Baxalta Incorporated , Baxalta GmbH
发明人： Michael Dockal , Fritz Scheiflinger , Sabine Knappe , Susanne Till , Ton Hai , Paul Sanders
IPC分类号： A61K31/795 , A61K31/7024 , A61K31/37 , A61K31/727 , A61K38/37 , A61K38/48
CPC分类号： A61K31/795 , A61K31/37 , A61K31/7024 , A61K31/727 , A61K38/37 , A61K38/4846 , A61K2300/00
摘要： The present invention provides pharmaceutical formulations including a non-anticoagulant, non-saccharide polymer that with at least one sulfate or sulfonate moiety. The pharmaceutical formulations of the invention are of use to improve blood clotting in a subject. Also provided are useful analytical methods utilizing these polymers to query the dynamics of blood clotting in vitro.
-
公开(公告)号：US20200215099A1
公开(公告)日：2020-07-09
申请号：US16819770
申请日：2020-03-16
申请人： Baxalta Incorporated , Baxalta GmbH
发明人： Michael Dockal , Fritz Scheiflinger , Sabine Knappe , Susanne Till , Ton Hai , Paul Sanders , Prasad Dande , Cong Jiang
IPC分类号： A61K31/737 , A61K31/724 , A61P7/02 , C08B37/16 , C07H5/10 , A61K45/06 , A61K31/715
摘要： The present invention provides non-anticoagulant sulfated or sulfonated polysaccharides (NASPs), which accelerate the blood clotting process. Also provided are pharmaceutical formulations comprising a NASP of the invention in conjunction with a pharmaceutically acceptable excipient and, in various embodiments, these formulations are unit dosage formulations. The invention provides a NASP formulation, which is orally bioavailable. Also provided are methods for utilizing the compounds and formulations of the invention to promote blood clotting in vivo as therapeutic and prophylactic agents and in vitro as an aid to studies of the blood clotting process.
-
公开(公告)号：US20190125782A1
公开(公告)日：2019-05-02
申请号：US16224665
申请日：2018-12-18
申请人： Baxalta Incorporated , Baxalta GmbH
发明人： Michael Dockal , Fritz Scheiflinger , Sabine Knappe , Susanne Till , Ton Hai , Paul Sanders , Prasad Dande , Cong Jiang
IPC分类号： A61K31/737 , A61K31/715 , C07H5/10 , C08B37/16 , A61K45/06
摘要： The present invention provides non-anticoagulant sulfated or sulfonated polysaccharides (NASPs), which accelerate the blood clotting process. Also provided are pharmaceutical formulations comprising a NASP of the invention in conjunction with a pharmaceutically acceptable excipient and, in various embodiments, these formulations are unit dosage formulations. The invention provides a NASP formulation, which is orally bioavailable. Also provided are methods for utilizing the compounds and formulations of the invention to promote blood clotting in vivo as therapeutic and prophylactic agents and in vitro as an aid to studies of the blood clotting process.
-
公开(公告)号：US11160850B2
公开(公告)日：2021-11-02
申请号：US16231195
申请日：2018-12-21
申请人： Baxalta Incorporated , Baxalta GmbH
摘要： Disclosed herein are compositions and methods for improving hemostasis in the treatment of bleeding disorders and reversal of anticoagulant activity. Effective ratios of prothrombin (FII) and activated factor X (FXa) for the treatment of bleeding disorders that are as efficacious as FEIBA®, but require a lower concentration of FII are described herein.
-
公开(公告)号：US20190381092A1
公开(公告)日：2019-12-19
申请号：US16457450
申请日：2019-06-28
申请人： Baxalta Incorporated , Baxalta GmbH
发明人： Michael Dockal , Fritz Scheiflinger , Sabine Knappe , Susanne Till , Ton Hai , Paul Sanders
IPC分类号： A61K31/795 , A61K9/00 , A61P7/04
摘要： The present invention provides pharmaceutical formulations including a non-anticoagulant, non-saccharide polymer that with at least one sulfate or sulfonate moiety. The pharmaceutical formulations of the invention are of use to improve blood clotting in a subject. Also provided are useful analytical methods utilizing these polymers to query the dynamics of blood clotting in vitro.
-
7.发明申请公开(公告)号：US20190231855A1
公开(公告)日：2019-08-01
申请号：US16231195
申请日：2018-12-21
申请人： Baxalta Incorporated , Baxalta GmbH
CPC分类号： A61K38/4833 , A61K38/4846 , A61K38/54 , C12Y304/21005 , C12Y304/21006
摘要： Disclosed herein are compositions and methods for improving hemostasis in the treatment of bleeding disorders and reversal of anticoagulant activity. Effective ratios of prothrombin (FII) and activated factor X (FXa) for the treatment of bleeding disorders that are as efficacious as FEIBA®, but require a lower concentration of FII are described herein.
-
公开(公告)号：US20180256634A1
公开(公告)日：2018-09-13
申请号：US15977956
申请日：2018-05-11
申请人： Baxalta Incorporated , Baxalta GmbH
发明人： Michael Dockal , Fritz Scheiflinger , Sabine Knappe , Susanne Till , Ton Hai , Paul Sanders , Prasad Dande , Cong Jiang
IPC分类号： A61K31/737 , C08B37/16 , A61K45/06 , C07H5/10 , A61K31/715
CPC分类号： A61K31/737 , A61K31/715 , A61K45/06 , C07H5/10 , C08B37/0012 , A61K2300/00
摘要： The present invention provides non-anticoagulant sulfated or sulfonated polysaccharides (NASPs), which accelerate the blood clotting process. Also provided are pharmaceutical formulations comprising a NASP of the invention in conjunction with a pharmaceutically acceptable excipient and, in various embodiments, these formulations are unit dosage formulations. The invention provides a NASP formulation, which is orally bioavailable. Also provided are methods for utilizing the compounds and formulations of the invention to promote blood clotting in vivo as therapeutic and prophylactic agents and in vitro as an aid to studies of the blood clotting process.
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.018 秒)
